



8400 10/22/01 1616 (4)
Docket No.: A 13470 US (C36368/125381)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :
Andreas NATSCH

Serial No.: 09/928,630

Filed: August 13, 2001

For: **ANTIBACTERIAL COMPOSITION**

)
) Examiner: Unassigned
) Art Unit: 1616
)

RECEIVED
OCT 18 2001
TECH CENTER 1600/2900

New York, New York
October 10, 2001

TRANSMITTAL OF PRIORITY DOCUMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:


Enclosed please find a certified copy of the following priority document:

1. Appln. No. 00117496.0, filed August 14, 2000, in Europe.


Applicants claim priority based on the aforesaid application under the provisions

of 35 U.S.C. Section 119.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231, on October 10, 2001.


Stephen J. Brown, Reg. No. 43,519

Respectfully submitted,

By: 
Stephen J. Brown
Registration No. 43,519
BRYAN CAVE LLP
245 Park Avenue
New York, NY 10167-0034
(212) 692-1800

THIS PAGE BLANK (USPTO)



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

Bescheinigung

Certificate

Attestation

RECEIVED
OCT 18 2001
TECH CENTER 1600/2900

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

00117496.0

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

I.L.C. HATTEN-HECKMAN

DEN HAAG, DEN
THE HAGUE, 06/09/01
LA HAYE, LE

THIS PAGE BLANK (USPTO)



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation

Anmeldung Nr.:
Application no.: 00117496.0
Demande n°:

Anmeldetag:
Date of filing: 14/08/00 ✓
Date de dépôt:

Anmelder:
Applicant(s):
Demandeur(s):
Givaudan SA
1214 Vernier-Genève
SWITZERLAND

Bezeichnung der Erfindung:
Title of the invention:
Titre de l'invention:
Antibacterial composition comprising Sandela

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat:
State:
Pays:

Tag:
Date:
Date:

Aktenzeichen:
File no.
Numéro de dépôt:

Internationale Patentklassifikation:
International Patent classification:
Classification internationale des brevets:
A01N31/06, A61K7/32, A61K7/46

Am Anmeldetag benannte Vertragsstaaten:
Contracting states designated at date of filing: AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE/TR ✓
Etats contractants désignés lors du dépôt:

Bemerkungen:
Remarks:
Remarques:

See for original title of the application page 1 of the description.

THIS PAGE BLANK (USPTO)

Antibacterial composition

The present invention relates to an antibacterial composition.

5 Body malodor is formed when fresh perspiration, which is odorless per se, is decomposed by bacteria such as *Staphylococci* and *Corynebacteria*, both genera belonging to the gram-positive *Eubacteriaceae*.

10 Cosmetic deodorants are intended to inhibit formation of axillary body malodor. They are based on different active principles. One principle is the suppression of perspiration by astringents. According to a second principle the bacterial flora on the skin is reduced by antibacterial substances. But many commercially used
15 antibacterial compounds affect the entire microbial flora on the skin. In addition some agents have higher activity against the low-odor forming *Staphylococci* bacteria than against the *Corynebacteria* and may thus favour the latter, which is highly undesirable.

20 Foot deodorants and deodorants for shoes are used to prevent the formation of a typical cheesy smell of feet. This odor is formed by *Brevibacteria* under prolonged periods of humidity which may occur especially in individuals with excessive transpiration or in shoes with insufficient aeration.

25 Another skin manifestation attributed to a bacterial origin is acne, which is commonly treated with topically applied cosmetic products containing antibacterial agents.

- 2 -

Antibacterial compounds currently used in deodorant or antiperspirant products include for example Triclosan (2,4,4'-trichloro-2'-hydroxy-diphenyl-ether). However, the use of such chlorinated compounds as antibacterial agents are strongly questioned by consumer organisations.

Antibacterial properties of certain odoriferous substances, essential oils or other fragrance ingredients are known to be used to manufacture deodorising fragrance compositions. One natural fragrance compound with particularly high activity is 3,7,11-trimethyl-2,6,10-dodecatrien-1-ol (Farnesol). Its use in deodorising fragrance compositions has been described in DE 27 28 921 B2 and DE 33 15 058 A1. However, to obtain its antibacterial effect, higher levels than the ones used in customary perfumery need to be employed.

Another natural fragrance ingredient known for its antibacterial activity is Sandalwood oil. In a recent study by Viollon et Chaumont (Parfums & cosmétiques, 1994, 116:67-70) the antibacterial activity against axilla bacteria of 26 essential oils were compared. Among them Sandalwood oil has the strongest activity. However, high price and limited availability of this natural oil hamper its widespread use in commercial cosmetic products at levels needed for a growth inhibition of skin bacteria.

It is an object of the present invention to replace the expensive Sandalwood oil by a less expensive substance.

Further it is an object of the present invention to provide a composition having an antibacterial effect against *Corynebacteria*.


- 3 -

Further it is an object of the present invention to provide a composition having an antibacterial effect against *Staphylococci*.

Further it is an object of the present invention to
5 provide a composition having an antibacterial effect against *Brevibacteria*.

Further it is an object of the present invention to provide a composition having an antibacterial effect against *Propionibacteria*.

10 The present invention is based on the surprising finding that among 250 commonly used fragrance raw materials Sandela (3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol) of the formula I



15 is the most active compound against a collection of *Corynebacterium* sp. strains isolated from healthy human volunteers with an activity even slightly higher than Sandalwood oil, and only slightly below the one of Farnesol. The activity of this compound is significantly
20 higher than e.g. the activity of Sandalore and Radjanol. It was shown that among the tested fragrance compounds with Sandalwood odor, Sandela offers both, outstanding olfactive properties as well as an excellent antibacterial activity. Furthermore the intensity of the antibacterial
25 effect against *Corynebacteria* and *Staphylococcus* is equal, which is not the case for Triclosan. The latter compound is much more active for the low-odor forming *Staphylococci* then for the *Corynebacteria*, and application of low

- 4 -

amounts of this compound may thus favour populations of *Corynebacteria*.

Further it was shown, that Sandela has also strong antibacterial properties against *Brevibacterium*
5 *epidermidis*, the organism involved in formation of foot odor. Sandela is an appropriate synthetic molecule with sandelwood odor to control this organism. Its activity is equal as natural Sandalwood oil and 2 to 6 times higher than the synthetics Radjanol and Sandalore. Therefore
10 Sandela can inhibit formation of different kinds of body malodor.

Furthermore it was shown, that Sandela has good antibacterial properties against *Propionibacterium acnes* as well. Therefore it is useful for prevention and
15 treatment of acne.

Odoriferous substances are by definition volatile compounds which evaporate from the skin and therefore loose their deodorising effect. Furthermore small water-soluble fragrance compounds can get dissolved in sweat and
20 are thus rapidly diluted under conditions of high sweat secretion which further reduces the duration of the deodorising effect. Therefore a low water solubility indicated by a high LogP value and a low volatility indicated by low vapour pressure are desired for
25 odoriferous substances which are used for their antibacterial activity. Indeed it has been found that Sandela, besides exhibiting pronounced antibacterial activity, meets these criteria. It has a vapour pressure of 2.2 µg/L and a calculated LogP of 5.27. Regarding this
30 it is similar to Farnesol, which has a vapour pressure of 1.35 µg/L and a calculated LogP value of 5.31. Compared to

- 5 -

e.g. the common antibacterial perfume ingredient Eugenol with a vapour pressure of 109 $\mu\text{g/L}$ and a calculated LogP of 2.2 its deodorant activity is therefore maintained over a prolonged period of time when it is applied to the skin.

5 Since products which exert an antibacterial activity by means of individual fragrance compounds employ higher levels of these compounds than the ones used in customary perfumery, these antibacterial compounds must meet several further criteria. They should have a relatively low odor
10 value, i.e. they should only be perceived when used at higher amounts in order to not affecting the olfactive balance of the fragrance composition too much. The odor value is defined as the vapour pressure (in ng/L) divided by the olfactive threshold value (in ng/L) and it
15 corresponds to the dilution factor above threshold (DFT). It was found, that Sandela has an odor value of 265, whereas Sandalore has an odor value of 5685, Ebanol has an odor value of 212557 and the odor value of Radjanol is 53130. Santalol, the main active ingredient of Sandalwood
20 oil, has an olfactive value of 650 and Eugenol has even an odor value of 346904. Sandela therefore meets the criterion of low odor value and its olfactive impact on the fragrance is much lower compared to other compounds with Sandalwood odor like Sandalore and Ebanol or other
25 antibacterial perfume components like Eugenol. Thus it may be incorporated in quantities sufficiently high to obtain good antimicrobial activity in perfumes without affecting the overall impression too much. This would not be the case for other synthetic fragrance molecules with low
30 threshold like Ebanol and Sandalore. Finally, its sandalwood note is highly desirable as a base note for perfumes applied to the human body.

- 6 -

Such perfume compositions need a Sandela level which is higher than the one used in customary perfumery. The recommended level in the final product should ideally be between 0.3% to 0.6%. If the perfume level in the
5 deodorising or antiperspirant product is kept at 1%, the perfume should contain between 30% and 60% of Sandela. If the perfume level in the product is 1.5%, the perfume components consists preferably of 20 to 40% Sandela. However to obtain stronger effects the use level may be
10 increased to 1% in the finished deodorant or antiperspirant product. Finally, if Sandela is used in combination with other antibacterial fragrance materials the level in the final product may be lowered to 0.1%.

Sandela does not need to be added to the perfume, but can
15 also be added directly as an active ingredient to the deodorant or antiperspirant product. In this case Sandela is added as an ingredient separate from the perfume composition to the deodorant or antiperspirant formula at a level of 0.1 to 1%.

20 The colourless viscous liquid Sandela is obtained by a two step reaction, wherein Camphene and Guaiacol are treated with an acidic catalyst followed by hydrogenation (US patent 3'499'937) and its preparation is relatively cheap.

Furthermore it was tested whether Sandela can be combined
25 with other antibacterial agents currently used for their deodorising action to reduce usage levels of these compounds or to improve their antibacterial effects. It was found that Sandela does not enhance the activity of Triclosan, which may be due to a completely different mode
30 of action of these two compounds. It appears therefore not

- 7 -

useful to combine these two materials to improve the deodorant efficiency of a product.

Sandela can be used for partially replacing Farnesol in antibacterial fragrance compositions. Indeed, these two products can be combined in any ratio adding up their antibacterial effect. The invention thus further relates to the use of Sandela to reduce usage level of Farnesol. Due to the four times lower price of Sandela compared to Farnesol, this results in significant cost savings and an improvement of the overall olfactive performance of the perfume. Like Sandela, Farnesol can be added as an ingredient of the perfume composition or separately from the perfume components. In fragrance compositions comprising Sandela and Farnesol, the level of Sandela is preferably between 10 and 80%, the level of Farnesol between 5 and 50%.

Sandela cannot be employed only for cost savings and improved olfactive performance, it can be used to enhance the antibacterial effect of Farnesol as well. By keeping normal use levels of Farnesol, which is used as separate ingredient of the deodorant or antiperspirant product, and combining this with a perfume with high Sandela content, an enhanced antibacterial effect can be obtained. The invention thus also relates to the use of high levels of Sandela as well as Farnesol in deodorant and antiperspirant products to obtain increased deodorant effects.

Sandela compositions may be formulated in various forms such as deodorant stick, roll-on, pump-spray, aerosol, deodorant soap, powder, solution, gel, cream, stick, balm

- 8 -

and lotion. These products are preferably used as personal care products.

- 9 -

Examples**Example 1.**

Comparison of the antibacterial activity of Sandela with other perfume ingredients and antibacterial agents when tested against human axilla bacteria.

The antibacterial efficacy of the relevant fragrance compounds mentioned in the present invention in microtiter plate tests is demonstrated below. The different bacterial strains had been isolated from the human axilla by current microbiological practice. They were taxonomically identified by cell morphology, gram-reaction and biochemical tests included in the Api coryne test kit (BioMerieux, France). Strain *Staphylococcus epidermidis* Ax25 was identified by fatty acid methyl ester analysis (FAME; German type strain collection DSMZ, Germany). The strains were maintained on Tryptic soy broth plates, this standard medium being amended with 5 g per Litre of Tween 80 and 1 g of Soybean lecithin. Plates were incubated at 36° C for a period 48 hours. The bacteria were then swabbed from the plates and suspended in 4 ml of Müller-Hinton broth amended with 100 mg of Tween80 per Litre (MH-Tween) and incubated again at 36° C for 16 hours. Following incubation the bacterial suspensions were diluted in MH-Tween to obtain a final cell density of 10^6 colony forming units per ml. For each fragrance material four microtiter plates were used in the example, each microtiter plate having 8 rows, A-H, and 12 columns, 1-12. To each column a diluted suspension of a different test organism was distributed, 100 µl per well. 1% stock solutions of the fragrance materials were then prepared in MH-Tween broth. The fragrance material was dispersed by

- 10 -

ultrasonication into the aqueous medium to obtain a homogenous emulsion. 100 µl per well of this emulsion was then added to the first row of the microtiter plates already containing the target organisms. Serial dilution series were then prepared starting at row A and continuing until row G, each time removing 100 µl from a well and transferring it to the next well. In this way fragrance concentrations of 0.5%, 0.25%, 0.125%, 0.0625%, 0.03125%, 0.0156% and 0.0078% were tested for their antibacterial efficacy. The reference compound Triclosan was tested at 16 fold lower concentrations. The plates were covered with plastic films and incubated for 24 h at 36° C with shaking at 250 rpm. The turbidity developing in the microtiter plates was then examined after 24 h to determine microbial growth. The minimal concentration of fragrance inhibiting the growth of an organism by at least 80% was determined as the minimal inhibitory concentration (MIC).

Table 1. Minimal inhibitory concentration (MIC) for bacteria derived from the human axilla of relevant perfume raw materials described in this study. Data are expressed in % weight/ volume

	Ax 25	Ax26	Ax3	Ax7	Ax10	Ax11	Ax12	Ax15	Ax20	Ax19
Sandela	0.0234	0.0156	0.0176	0.0273	0.0137	0.0273	0.0137	0.0234	0.0273	0.0086
Farnesol	0.0156	0.0078	0.0156	0.0137	0.0078	0.0195	0.0137	0.0156	0.0137	0.0156
Sandal-wood oil	0.0313	0.0156	0.0195	0.0313	0.0164	0.0313	0.0313	0.0313	0.0313	0.0313
Sandalore	0.1250	0.1250	0.1250	0.1250	0.1250	0.1250	0.1250	0.2500	0.1250	n.d.
Radjanol	0.1250	0.0625	n.t.	0.0625	n.t.	n.t.	n.t.	0.125.	n.t.	n.t.

- 11 -

Ebanol	0.1250	0.1250	0.1250	0.1250	0.2500	0.2500	0.2500	0.2500	0.1250	n.d.
Triclosan	0.000015	0.0015	0.0029	0.0029	0.0020	0.0029	0.0017	0.0029	0.0107	0.0039

Ax 25 was identified as *Staphylococcus epidermidis* by FAME analysis. Identification with the Api Coryne test kit yielded the following species assignments for the remainder of the strains: Ax 26 *Corynebacterium* sp.; Ax 3 *Corynebacterium bovis*; Ax 7 *Corynebacterium* group G; Ax 10 *Corynebacterium jeikeium*; Ax 11 *Corynebacterium jeikeium*; Ax 12 *Corynebacterium jeikeium*; Ax 15 *Corynebacterium jeikeium*; Ax 20 *Corynebacterium striatum/amycolatum*; Ax 19 *Corynebacterium jeikeium*. The strains were isolated from the axilla of 8 human volunteers. Based on biochemical tests and colony morphology all strains were distinct from each other, even the several strains all belonging to *Corynebacterium jeikeium*.

15

Example 2. Antibacterial activity against *Brevibacterium epidermidis*

A selection of perfume compounds were tested against *Brevibacterium epidermidis* DSMZ 9586 (German Collection of Microorganisms and Cell Cultures) with the method described in Example 1. The MIC value obtained for Sandela is comparable with the values reported for the axilla bacteria, and it is thus appropriate to use this perfume compound also in deodorant products intended to prevent the cheesy smell of feet and shoes.

- 12 -

	MIC (% w/v) for <i>Brevibacterium epidermidis</i>
Sandela	0.0156
Sandalore	0.0937
Sandalwood oil	0.0156
Radjanol	0.03125
Farnesol	0.0078
Triclosan	0.003125

Example 3. Antibacterial activity against *Propionibacterium acnes*

5 A selection of perfume compounds were tested against *Propionibacterium acnes* DSMZ1897 (German Collection of Microorganisms and Cell Cultures) with the method described in Example 1, with the exception that the organism was grown under anaerobic conditions during 72 hours until evaluation of results.

10

	MIC (% w/v) for <i>Propionibacterium acnes</i>
Sandela	0.03125
Sandalore	0.25
Sandalwood oil	0.0156

- 13 -

Farnesol	0.0078
Triclosan	0.00039

Example 4. Comparison of the antibacterial action of perfume oils with high Sandela and Farnesol content

- 5 Perfume compositions with high Sandela and/or Farnesol content were prepared as described in Table 2. These are typical perfumes to be incorporated in cosmetic products with deodorant or antiperspirant action. The MIC of these perfume compositions against a selection of the test
- 10 organisms was tested with the method described in Example 1. The results are summarised in Table 3. Indeed these perfumes have a MIC between 0.025% and 0.05% which indicates strong antibacterial activity. Furthermore it becomes evident from these data, that Farnesol can be
- 15 partially or fully replaced with Sandela in a perfume composition without losing the activity significantly. Finally, adding Farnesol in addition to Sandela further enhances the activity of such compositions.

20 **Table 2. Composition of deodorant perfumes**

Ingredient Name	Parts in composition			
	A	B	C	D
ACET CEDRENYL 70	60	60	60	43
ACET LINALYLE SYNT	30	30	30	21

- 14 -

ACET P T BUTYL CYCLOHEXYLE	55	55	55	39
ADOXAL at 10% in DPG	2	2	2	1
ALD PHENYL ACETIQUE 85%/APE	10	10	10	7
ALLYL AMYL GLYCOLATE	12	12	12	9
AMBROFIX at 10% in DPG	4	4	4	3
BRASSYLATE ETHYLENE	20	20	20	14
CEDRYL METHYL ETHER	20	20	20	14
CITRAL SYNT 80%/ORANGE TERPENES	1	1	1	1
DIHYDRO MYRCENOL	130	130	130	93
EVERNYL	1	1	1	1
FARNESOL	400	0	200	200
GERANIOL	20	20	20	14
GERANIUM ESS AFRIQUE	20	20	20	14
ISO E SUPER	100	100	100	71
LILIAL	120	120	120	86
LINALOL SYNT	50	50	50	37
SALICYLATE HEXENYLE-3- CIS	15	15	15	11

- 15 -

SANDELA	0	400	200	400
TROPIONAL	30	30	30	21
Total	1100	1100	1100	1100

Table 3. Antibacterial activity of deodorant perfumes

	A	B	C	D
Ax 25 (S. epidermidis)	0.0625	0.0625	0.0625	0.03125
Ax26 (Corynebacterium xerosis)	0.02343	0.0625	0.0117	0.0156
Ax 7 (Corynebacterium group G)	0.03125	0.03125	0.03125	0.03125
Ax15 (Corynebacterium jeikeium)	0.03125	0.03125	0.03125	0.03125
average	0.037108	0.046875	0.034175	0.027338

5

Example 5. Antibacterial activity of Deodorant Roll-on formula incorporating antibacterial perfumes

Non-alcoholic deodorant compositions for Roll-on deodorants were prepared as described in Table 4. The
 10 Deodorants were ammended with 1.4% of the perfumes according to the present invention which were described in Example 4. The antibacterial activity of the deodorants

- 16 -

was determined according to the procedure described in Example 1. Instead of using emulsions of the perfume products in MH-Tween, 100 µl of the finished deodorant was added to the first well of the Microtiter plates
5 containing the target organisms. Dilution series of this finished product were thus prepared in MH-Tween, and growth of the microorganisms in these product solutions were monitored.

10 **Table 4. Composition of Deodorants containing perfumes according the present invention**

	Hydroxyethylcellulose	0.30
	Water	62.1
	Dipropylene Glycol	30.00
15	Propylene Glycol	5.00
	PEG 40 hydrogenated Castor oil	2.50
	Tetrasodium EDTA	0.10
	Citric acid	qsp pH= 5.50
	Fragrance	1.4

20

Hydroxyethylcellulose was dispersed in water at 35°C till homogeneous. PEG 40 hydrogenated Castor oil was mixed with dipropylene glycol and propylene glycol and this mixture was added. The remaining constituents were added
25 afterwards.

- 17 -

Table 5. Growth inhibitory effect of the Deodorant formula according to table 4 with the perfume compositions described in Example 4.

	No perfume	1.4% perfume B	1.4% perfume C	1.4% perfume A
Staphylococcus epidermidis Ax 25	11	38	32	64
Corynebacterium xerosis Ax 26	10	45	45	128
Corynebacterium group G Ax10	27	54	54	128
Corynebacterium jeikeium Ax 15	27	54	32	64

5

1) Given is the maximal dilution of the product which still inhibits the growth of the axilla bacteria

10 Example 6: Further examples of deodorants

The following sets forth examples for the use of perfume compositions according to the present invention in various products. The methods of preparing the following compositions are well known to those skilled in the art.

- 18 -

All formulations may contain additional ingredients known to those skilled in the art, e.g. colorants, opacifiers, buffers, antioxidants, vitamins, emulsifiers, UV absorbers, silicones and the like. All products can also
 5 be buffered to the desired pH. All values are % w/w.

Deo-colognes:

Fragrance	0.5 - 10.0
Ethanol	to 100.0

Deo-Sticks:

10

Antiperspirant stick:

Ethylene Glycol Monostearate	7.0
Shea butter	3.0
Neobee 1053 (PVO International)	12.0
Generol 122 (Henkel)	5.0
Kesscowax B (Akzo)	17.0
Dimethicone Dow Corning 345	35.0
Aluminium Sesquichlorhydrate	20.0
Fragrance	1.0

Antiperspirant stick

Stearyl Alcohol	17.0
-----------------	------

- 19 -

Castor Wax	3.0
Talc	5.0
Aluminum Zirconium Tetrachlorhydrate	20.0
Fragrance	1.0
Dimethicone Dow 245	to 100.0

Clear Deodorant Stick

Witconol APM	43.0
Propylene Glycol	20.0
Alcohol 39C	21.0
Water	7.0
Monamid 150ADD	5.0
Millithix 925	2.0
Ottasept Extra	0.5
Fragrance	1.5

Deodorant Stick

Propylene Glycol	69.0
Water	21.5
Sodium Stearate	8.0

- 20 -

Fragrance	1.5
-----------	-----

Alcohol free Deodorant Stick

Propylene Glycol-3 Myristyl Ether (Witconol APM)	36.0
Propylene Glycol	36.0
Water	19.0
Sodium Stearate	7.75
Fragrance	1.25

Antiperspirant Aerosol

Absolute Ethanol	15.0
Zirconium Aluminum tetrachlorhydrate	5.0
Bentone 38	1.5
Fragrance	1.25
S-31 Hydrocarbon propellant	to 100

5

Antiperspirant Pump

Water	57.0
Aluminum Sesquichlorhydrate	20.0
Triton X-102 (Union Carbide)	2.0

- 21 -

Dimethyl Isosorbide (ICI)	20.0
Fragrance	1.0

Roll-On

Dimethicone DC 354 (Dow Corning)	69.0
Bentone 38	10.0
Rezal 36 GP (Reheis Chem. Co.)	20.0
Fragrance	1.0

In all these compositions, the fragrance contains from 10-
5 60% of Sandela and from 0 -50% of Farnesol.

In the above, the following components were used:

	Neobee 1053	glycerol tricaprato/caprylate
10	Generol 122	soya sterol
	Kesscowax B	cetyl alcohol and glycol polymer
	Witconol APM	polypropylene glycol-3 myristyl ether
	Monamid 150ADD	cocoamide diethanolamine
	Millithix 925	dibenzylidene sorbitol
15	Ottasept Extra	quaternium 18 hectorite

- 22 -

Bentone 38 quaternium 18 hectorite

Triton X-102 octoxynol-13

Dimethicone DC 354 mixture of fully methylated linear
siloxane polymers end-blocked

5 with trimethylsiloxo units

Rezal 36 GP aluminium
zirconiumtetrachlorohydrexglycine

10

14. Aug. 2000

- 23 -

Claims

1. An antibacterial composition comprising 3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol as active component.
- 5 2. Composition according to claim 1, comprising 0.1 to 1% by weight of 3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol.
3. Composition according to claim 1 or 2, comprising 0.3 to 0.6% by weight of 3-(5,5,6-trimethyl-
10 bicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol.
4. Composition according to one of the claims 1 to 3 comprising additionally 3,7,11-trimethyl-2,6,10-dodecatrien-1-ol.
5. Composition according to one of the claims 1 to 4
15 comprising perfume components comprising 10 to 80% by weight of 3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol.
6. Composition according to one of the claims 1 to 5
20 containing perfume components consisting of 10 to 80% by weight of 3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol as the only antibacterial agent.
7. Composition according to one of the claims 1 to 6
25 containing perfume components consisting of 10 to 80% by weight of 3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol and 5 to 50 % of 3,7,11-trimethyl-2,6,10-dodecatrien-1-ol.

- 24 -

8. A personal care product comprising a composition according to one of the claims 1 to 7.
9. A malodor inhibiting product according to claim 8.
10. An acne inhibiting product according to claim 8.
- 5 11. A deodorant and/or an antiperspirant product according to claim 8.
12. Method for preparing a product according to claim 8 by admixing all ingredients and adding 3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol
10 together with fragrance components.
13. Method for preparing a product according to claim 8 by admixing all ingredients, adding 3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol
15 together with fragrance components and adding 3,7,11-trimethyl-2,6,10-dodecatrien-1-ol separately.
14. Method for preparing a product according to claim 8 by admixing all ingredients, adding 3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexan-1-ol separately from fragrance components.

Abstract

The present invention relates to an antibacterial composition comprising Sandela as active ingredient. Sandela has an antibacterial effect against
5 *Corynebacteria*, *Staphylococci*, and *Brevibacteria*. Therefore Sandela can inhibit formation of different kinds of body malodor. Further due to its activity against *Propionibacteria*, Sandela may be used in products for prevention and treatment of acne.

10

THIS PAGE BLANK (USPTO)